Scientists may have found the cure for baldness

Around four in 10 men suffer male pattern baldness by the age of 45 and two thirds by the age of 60

Around four in 10 men suffer male pattern baldness by the age of 45 and two thirds by the age of 60

Further study led the team to WAY-316606, a compound used to treat osteoporosis. In the USA, there are around 50 million men and 30 million women affected by hair loss, which United Kingdom -based researchers said could be the source of "psychological distress".

There are now only a couple of drugs available to treat male-pattern baldness, but they're not very effective and can cause side effects so more therapies are needed.

The only other option left for people is hair transplantation surgery, which is a long procedure, is expensive, and also painful. It could also be used to treat women with alopecia.

A project by The University of Manchester's Centre for Dermatology Research in England began work by examining an immunosuppressive drug that had always been known to cause hair growth as a side effect.

"That creates our analysis clinically really relevant, as most hair loss lookup studies merely utilize cell civilization", he explained.




Male pattern baldness affects around half of all men by the age of 50 and usually manifests as a receding hairline and/or hair, whereas the less common female pattern baldness usually takes the form of thinning hair. CsA often has severe side-effects, the least serious - but most interesting - of which is that it enhances cosmetically unwanted hair growth.

The researchers, from the University of Manchester, first latched onto an old immunosuppressive drug, cyclosporine A, used since the 1980s to prevent transplant organ rejection and reduce symptoms of autoimmune disease. Both preparations are especially effective and cause side effects. It stimulates and enhances the hair follicles to grow. Follicles which were not treated with the drug only achieved growth of 1.5mm over the same period.

It works by blocking a naturally-occurring protein that kills off growth and plays a key role in male baldness. The brittle bone drug formulation was administered to the hair follicles for six consecutive days.

The next step, Dr Hawkshaw states, is for a clinical trial to be undertaken so it can be determined whether or not WAY-316606 is safe, and if it will end up finding its way into the hands, and scalps, of consumers.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.